Mayo Clinic Platform Puts AI Decision Support Inside the EHR

Good morning, HealthTech insiders. Healthcare technology is moving beyond standalone tools and becoming part of how care is delivered and hospitals are run.

On Tuesday, Mayo Clinic Platform launched an AI-powered clinical decision support chat and 22 clinical calculators integrated directly into electronic health records, giving clinicians access to guidance without leaving their workflow. LeanTaaS acquired LookDeep Health to combine AI-powered patient monitoring with hospital operations software, while Hinge Health reported 52% revenue growth and a 33% non-GAAP operating margin, showing that digital care can grow while maintaining profitability.

Today's Signal looks at three different approaches to the same opportunity: making technology more valuable by embedding it into everyday healthcare operations.

In today's Signal:

• Mayo Clinic Platform launches an EHR-integrated Clinical Decision Support solution: a specialty chat covering 35+ specialties, updated daily, plus 22 clinical calculators.

• LeanTaaS acquires LookDeep Health and launches iQueue for Virtual Care, its second acquisition in about two months.

• Hinge Health reports $235M in Q3 revenue, up 52%, raises its 2026 outlook and says it is open to hardware acquisitions.

• Plus: Samsung's upgraded sleep apnea feature reaches the Galaxy Ring, Humana and athenahealth take electronic prior auth nationwide, and DocMorris adds smartphone vital signs checks.

In partnership with

A Single Typo Shouldn’t Cost You a Sale

A shopper types “running shos” and gets nothing back. Another types “red waterprof trail runners under $150” and hits the same wall. Both knew what they wanted.

Traditional site search relies on exact keyword matching, leaving shoppers stranded at “0 results found” screens.

Gladly understands what shoppers mean, typos and all. Instead of a dead end, they get products that fit what they asked for and a conversation that keeps them shopping.

See how Gladly turns dead-end searches into sales

Turn Dead Ends Into Sales

CLINICAL AI
1. Mayo Clinic Platform Puts AI Decision Support Inside the EHR

On November 3, Mayo Clinic Platform launched an AI-enabled Clinical Decision Support (CDS) solution that brings Mayo Clinic knowledge and evidence-informed guidance directly into clinicians' workflows. It can be integrated within a growing number of EHR environments and is available to Mayo Clinic clinicians and to organizations in Mayo Clinic Platform's healthcare provider programs, starting this month.

The details:

• The core tool is a specialty-specific chat powered by a large language model. It covers more than 35 specialties, reflects Mayo's subspecialty model of care, cites peer-reviewed literature in its responses and is updated daily.

• It ships with 22 clinical calculators, reachable through chat or voice dictation, including proprietary Mayo Clinic-developed calculators. The calculators provide industry-standard medical information and evidence-based support on clinical questions in the patient care context, per Mayo.

• "The CDS solution is designed to assist healthcare professionals as they make patient care decisions; it does not replace clinical judgment," said Gelareh Zadeh, M.D., Ph.D., Chief Medical Officer for Mayo Clinic Platform. COO Maneesh Goyal framed the goal as less time "searching for information across multiple resources."

The Signal: Clinical reference used to be something you subscribed to and opened in another window. Mayo is turning its brand and its subspecialty expertise into a layer that lives in the chart, sold through its platform network rather than as a standalone app. That puts it in direct contact with the AI evidence tools clinicians already use on their phones. The question buyers will ask is the one Mayo has not answered yet: which EHRs, at what price, and with what evidence that answers change care.

HOSPITAL OPERATIONS
2. LeanTaaS Buys LookDeep to Bring Computer Vision Into Hospital Operations

LeanTaaS, whose iQueue software helps hospitals schedule operating rooms, infusion chairs and inpatient beds, announced on November 3 that it acquired LookDeep Health, a computer vision company for virtual patient monitoring. It also launched iQueue for Virtual Care, with three offerings: Virtual Observation, Virtual Nursing and Virtual Medicine. Terms were not disclosed.

The details:

• It is LeanTaaS's second acquisition in about two months, after Aidin. LookDeep's vision AI works with compatible existing cameras and in-room devices and has been evaluated in peer-reviewed research in Frontiers in Imaging, per the company.

• LeanTaaS reports results across LookDeep deployments of more than 70% fewer falls, twice the nursing contact, 80% fewer medication errors and three times the cost savings versus traditional virtual sitting. These are company-reported figures. LeanTaaS says its software is used by nearly 200 health systems across more than 1,200 hospitals, centers and clinics.

• "A camera alone does not generate an ROI," CEO Mohan Giridharadas told Fierce Healthcare. "Nobody confuses the cameras with the car, but there is no self-driving car without them." LookDeep co-founder and former CEO Narinder Singh joins as SVP of ambient intelligence, and LeanTaaS plans to bring vision to inpatient flow and operating rooms next, then infusion centers.

The Signal: Virtual sitting has been sold as a staffing tool. LeanTaaS is reframing the camera as a sensor for the operations layer: if the system knows a patient is up, a bed is empty or a room is being cleaned, the scheduling software can act on it. That is a bigger prize than fall prevention, and a harder one. It also puts LeanTaaS on a collision course with the EHR vendors and virtual nursing specialists that already own parts of this workflow.

DIGITAL HEALTH
3. Hinge Health Grows Revenue 52% and Raises Its 2026 Outlook as It Moves Beyond MSK

Hinge Health (NYSE: HNGE) reported third quarter revenue of $235.0 million on November 2, up 52% from $154.2 million a year earlier and above its own guidance of $223 million to $225 million. Non-GAAP income from operations rose 154% to $77.2 million, a 33% non-GAAP operating margin, and free cash flow reached $112.7 million.

The details:

• Hinge raised its 2026 revenue guidance to $879 million to $881 million, about 50% growth at the midpoint, and guided Q4 revenue to $249 million to $251 million. Clients rose 28% to 3,270.

• The company is extending its MSK platform into migraine and gastrointestinal care, after buying Cylinder Health for $105 million in cash in August. It targets summer 2027 for the fully integrated GI product, per Fierce Healthcare. Early migraine program results cited on the call: a 23% reduction in monthly migraine days.

• CEO Daniel Perez said the company is looking at hardware acquisitions: "I absolutely firmly believe you will not automate care delivery without also investing in hardware." President Jim Pursley steps down on January 1, 2027 and joins the board.

The Signal: For years the digital health question was whether anyone could make the unit economics work. Hinge is answering it with an 87% GAAP gross margin and a free cash flow margin near 48%, and it is spending that advantage on adjacent conditions sold to the same employers and plans. Point solutions in migraine, GI and pelvic health should take note: the buyer increasingly wants one contract, and Hinge has the cash to make that offer.

👀 WHAT WE'RE WATCHING NEXT

1. Which EHRs carry Mayo's CDS: Mayo says the tool integrates with a growing number of EHR environments but did not name them. We're watching for named EHR partners, pricing for provider program members and any published evaluation of how often clinicians act on its answers.

2. LeanTaaS takes vision into the OR: Giridharadas said inpatient flow and operating rooms come next, then infusion centers. We're watching for the first health system that ties camera signals to iQueue scheduling decisions, and for independent outcome data beyond company-reported results.

3. Hinge's next acquisition: Perez said Hinge will build organically first and use tuck-in M&A, particularly in hardware, when it speeds the timeline. We're watching Q4 results against the $249 million to $251 million guidance and the summer 2027 GI launch.

💰 FOLLOW THE MONEY

The deals:

• LeanTaaS: Acquired LookDeep, its second acquisition in roughly two months, adding AI-powered computer vision to its hospital operations platform used by nearly 200 health systems.

• Merck / Variational AI: Signed an AI drug discovery agreement worth up to $349M in upfront and milestone payments to develop small molecules against two undisclosed targets.

• Hinge Health: Generated $112.7M in quarterly free cash flow and is exploring hardware acquisitions to expand its digital musculoskeletal care platform.

• PhaseV: Launched BonV, a new platform designed to help biopharma companies make better clinical trial decisions using AI-driven analytics.

• Vitroscope: Raised $7M to develop technology that turns living human tissue into longitudinal drug discovery data.

The pattern: Capital is moving toward companies that control established workflows and proprietary data. LeanTaaS is expanding its hospital footprint, Merck is investing in AI-driven drug discovery, and Hinge Health is positioning its cash reserves for hardware expansion. Investors and strategic buyers are prioritizing distribution, differentiated data, and integration into existing operations over standalone AI models.

📆 UPCOMING HEALTHTECH EVENTS

• MEDICA 2026: November 16 to 19, 2026 · Messe Düsseldorf, Düsseldorf, Germany

  The world's largest medical technology trade fair, where European buyers see connected devices, monitoring and diagnostics side by side. Expect remote monitoring and smartphone vitals to be on the floor.

• 2026 Forbes Healthcare Summit: December 2, 2026 · New York, NY, with a virtual option

  A one-day gathering of health system, payer and investor leaders, a useful read on how executives are budgeting for AI going into 2027.

• HIMSS27 Global Health Conference & Exhibition: April 5 to 8, 2027 · McCormick Place, Chicago, IL

  The largest health IT gathering of the year, where EHR-integrated decision support and virtual nursing will be judged by CIOs, not press releases.

🛠️ Trending HealthTech AI Tools

• GE HealthCare Vscan Air Lung Guidance and AutoAS. Announced November 3 for the Vscan Air handheld ultrasound. Lung Guidance walks users through an eight-zone lung exam with landmark detection, automated capture and B-line scoring, and AutoAS estimates moderate to severe aortic stenosis from at least two cardiac views. Both are FDA 510(k)-cleared and CE-marked, per GE HealthCare.

• Glooko EndoTool IV Cloud. Commercially launched November 2: an FDA 510(k)-cleared, cloud-based inpatient IV insulin dosing tool that builds a patient-specific dosing model from labs and demographics and updates it with glucose trends, kidney function and insulin sensitivity. Recommendations assist, and do not replace, clinical judgment.

• Cerbo AI Scribe for virtual visits. Cerbo, an EHR for cash-pay and concierge practices, extended its native AI Scribe to Telemedicine and Zoom visits on November 3. It drafts a structured note inside the chart, and nothing commits to the record until the provider reviews and signs it.

🛠️ Trending HealthTech AI Startups

• PhaseV: A Cambridge, MA causal AI company for clinical development, founded in 2023 by CEO Raviv Pryluk, PhD. On November 3 it launched BonV, an agentic layer that turns a plain-language development question into a documented trial decision memo, with Forward Deployed Engineers working inside sponsor teams. Strategic interest: AI vendors are selling decisions to pharma, not dashboards.

• Variational AI: A generative chemistry company led by CEO Handol Kim. Its Enki platform will be fine-tuned on Merck's proprietary data to design small molecules for two undisclosed targets, in a collaboration worth up to $349M in upfront and milestone payments (Nov 2). Strategic interest: big pharma is licensing its own data into startup models.

• Vitroscope: A biotech company building perfusion platforms that keep living human tissue viable so researchers can follow immune activity and treatment responses for days, led by co-founder and CEO Carlo Kriesi. It raised $7M on November 3: a $5M seed co-led by Cerberus Ventures and YZR Capital plus $2M in non-dilutive funding from the Research Council of Norway. Its benchtop vitro.alive runs six parallel experiments, and vitro.scale (96 parallel experiments) is planned for 2028. Strategic interest: human tissue data is becoming a proprietary input for drug discovery AI.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

1. The Reference Desk Moves Into the Chart: Mayo Clinic Platform and the Fight for Point-of-Care Answers. What an EHR-native, subspecialty-tuned decision support layer changes for clinicians, CMIOs and the evidence tools already on their phones.

2. Cameras Are Not the Car: LeanTaaS, LookDeep and the Case for Vision as Hospital Infrastructure. Why a scheduling company bought a computer vision startup, what the company-reported numbers do and do not prove, and who stands in the way.

3. The Profitable Platform: What Hinge Health's Q3 Says About the Next Phase of Digital Care. A 33% non-GAAP operating margin, a move into migraine and GI, and an appetite for hardware: what it means for point solutions and their buyers.

That's it for today!

A decision support chat that lives in the chart, cameras that feed the scheduling engine, and a digital care company that sells more conditions to the same buyers. None of these moves is about a better model. Each one is about owning the place where work already happens.

That raises a hard question for every point solution: if the platform you plug into starts doing what you do, how long do you stay worth a separate contract?

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.